Mr. Sebastien Plouffe reports

DEFENCE THERAPEUTICS ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF UNITS FOR GROSS PROCEEDS OF $9,595,000

Defence Therapeutics Inc. has closed a private placement of 17,445,455 units at a price of 55 cents per unit for aggregate gross proceeds to Defence of $9,595,000.25. Each unit comprises one common share and one common share purchase warrant. Each warrant entitles its holder to acquire an additional common share of the company at a price of 65 cents per share for 24 months following the date of issuance.

As previously announced, the company executed a binding term sheet with two arm's-length institutional investors in connection with the private placement for aggregate gross proceeds of $6-million, pursuant to the terms and conditions of a sharing agreement dated and executed as of March 6, 2026. For more information, please see the company's press release dated Feb. 27, 2026.

All 10,909,091 warrants issued pursuant to the term sheet are exercisable at an exercise price of 65 cents per share for a period of 24 months following the closing date. The warrants include an equity blocker provision that prohibits the holder from exercising any portion of the warrants if such exercise would result in the holder owning more than 9.99 per cent of the company's outstanding shares. The Investors received a corporate finance fee of 654,546 units and a non-refundable deposit of 118,182 units at the private placement price in connection with the sharing agreement.

Defence intends to use the proceeds from the private placement to advance its antibody-drug conjugate (ADC) and radiopharmaceutical programs, to develop partnerships and for working capital purposes. No finders' fees were paid in connection with the private placement.

Pursuant to applicable Canadian securities laws and in accordance with the exchange policies, all securities issued under this private placement are subject to applicable resale restrictions under applicable securities laws. The private placement closed on March 6, 2026.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursuing cutting-edge science and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most.

We seek Safe Harbor.